Notice of Lead Plaintiff Deadline for Shareholders in the Athira Pharma, Inc. Class Action Lawsuit – ATHA

SAN DIEGO–(BUSINESS WIRE) – Robbins Geller Rudman & Dowd LLP announces that between September 18, 2020 and June 17, 2021, a class action lawsuit has been filed on behalf of the buyers of securities of Athira Pharma, Inc. (NASDAQ: ATHA) in the Western District of Washington has been. including (the “Class Period”). The case is entitled Wang v. Athira Pharma, Inc., No. 21-cv-00861 alleging that Athira Pharma and its CEO violated the Securities Exchange Act of 1934.

If you would like to appear as the lead plaintiff in the Athira Pharma class action or have any questions about your rights in relation to the Athira Pharma class action, please include your information here or contact attorney JC Sanchez of Robbins Geller at 800/449 -4900 or 619 / 231-1058 or by email to [email protected]. Motions by the lead plaintiffs for Athira Pharma’s class action lawsuit must be filed with the court by August 24, 2021 at the latest.

CASE ALERT: Athira Pharma is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration in people with devastating neurological conditions, including Alzheimer’s disease.

Athira Pharma’s class action alleges that during the class action period the defendants made false and misleading statements and failed to disclose: (1) the research conducted by Athira Pharma’s President and CEO, Defendant Leen Kawas, which formed the basis of the Product candidates and intellectual property have been tainted by Kawass’s scientific misconduct, including the manipulation of key data; and (2) as a result, Defendants’ positive statements about the business, operations and prospects of Athira Pharma were materially misleading and omitted essential facts necessary in order not to mislead the statements made.

On June 17, 2021, Athira Pharma issued a press release announcing that Athira Pharma’s board of directors had granted Kawas a temporary leave of absence pending a review of measures based on doctoral theses Kawas was doing while at Washington State University is done. An article published later that day in STAT News revealed that Kawas’ investigation was tied to allegations that she altered images in four separate articles related to her research on hepatocyte growth factor (HGF), a protein with the potential to treat Alzheimer’s disease and other neurological disorders. The article noted that although Athira Pharma “has since moved to a different molecule than the one Kawas was working on, it is still aimed at targeting HGF. And so with his PhD thesis, Kawas laid the biological foundations that Athira continues to use in her approach to treating Alzheimer’s. ”As a result of this news, Athira Pharma’s share price fell almost 39%, which harmed investors.

LEAD ACTION: The Private Securities Litigation Reform Act of 1995 allows any investor who has purchased Athira Pharma securities during the class action period to seek appointment as the lead plaintiff in Athira Pharma’s class action. A lead plaintiff is usually the applicant with the greatest financial interest in the legal protection sought by the alleged class, which is also typical and appropriate for the alleged class. One lead plaintiff is acting on behalf of all of the other class plaintiffs in directing Athira Pharma’s class action. The lead plaintiff can choose a law firm of their choice to bring Athira Pharma’s class action lawsuit. An investor’s ability to participate in a possible future collection of Athira Pharma’s class action lawsuit does not depend on whether they are the lead plaintiff.

ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: With 200 attorneys in 9 offices across the country, Robbins Geller Rudman & Dowd LLP is the largest US law firm serving investors in securities class actions. Robbins Geller’s attorneys have secured many of the largest shareholder recoveries in history, including the largest securities class action of all time – $ 7.2 billion – in In re Enron Corp. Sec. Lit. The 2020 ISS Securities Class Action Services Top 50 Report ranked Robbins Geller first for getting $ 1.6 billion back for investors last year, more than double the amount paid by any other securities plaintiff firm was drafted. More information is available at http://www.rgrdlaw.com.

Lawyer advertising.

Past results do not guarantee future results.

Services can be performed by lawyers in any of our offices.

Comments are closed.